Topline results from the FINEARTS-HF trial of finerenone showed a significant reduction in cardiovascular death and recurrent heart failure in patients with midrange and preserved left ventricular ejection fraction (LVEF). The new topline results suggest treatment with finerenone leads to a meaningful reduction in major adverse cardiovascular events…
